Eben Tessari Sells 45,042 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 45,042 shares of the company's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $30.51, for a total value of $1,374,231.42. Following the transaction, the chief operating officer now directly owns 72,363 shares of the company's stock, valued at approximately $2,207,795.13. This represents a 38.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Eben Tessari also recently made the following trade(s):

• On Monday, June 9th, Eben Tessari sold 10,319 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $30.38, for a total transaction of $313,491.22.
• On Tuesday, June 10th, Eben Tessari sold 15,506 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $30.46, for a total value of $472,312.76.
• On Monday, May 19th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $26.41, for a total value of $316,920.00.
• On Monday, April 14th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $20.48, for a total transaction of $245,760.00.

Kiniksa Pharmaceuticals Stock Performance

KNSA traded up $0.05 on Friday, reaching $27.78. The company had a trading volume of 228,912 shares, compared to its average volume of 629,670. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $17.38 and a fifty-two week high of $30.69. The company's fifty day moving average is $24.95 and its 200 day moving average is $22.13. The stock has a market cap of $2.03 billion, a P/E ratio of -198.38 and a beta of 0.06.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.09. The business had revenue of $137.79 million during the quarter, compared to analysts' expectations of $128.35 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. During the same quarter in the prior year, the firm earned ($0.25) EPS. The business's revenue for the quarter was up 72.5% compared to the same quarter last year. On average, sell-side analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Institutional Trading of Kiniksa Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Nuveen LLC bought a new position in Kiniksa Pharmaceuticals in the 1st quarter valued at $16,992,000. Acadian Asset Management LLC increased its stake in shares of Kiniksa Pharmaceuticals by 170.3% during the first quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company's stock valued at $22,961,000 after purchasing an additional 651,700 shares in the last quarter. Braidwell LP boosted its holdings in Kiniksa Pharmaceuticals by 19.3% in the fourth quarter. Braidwell LP now owns 3,452,447 shares of the company's stock worth $68,289,000 after acquiring an additional 557,934 shares in the last quarter. AQR Capital Management LLC raised its holdings in Kiniksa Pharmaceuticals by 149.1% in the first quarter. AQR Capital Management LLC now owns 491,761 shares of the company's stock worth $10,922,000 after buying an additional 294,319 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Kiniksa Pharmaceuticals by 138.9% during the fourth quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company's stock valued at $9,451,000 after purchasing an additional 277,827 shares in the last quarter. Hedge funds and other institutional investors own 53.95% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Wedbush reissued an "outperform" rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Jefferies Financial Group raised their target price on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Citigroup began coverage on Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They issued a "buy" rating and a $40.00 target price for the company. Finally, Wall Street Zen downgraded Kiniksa Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, June 6th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Kiniksa Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $38.80.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.